<?xml version="1.0" encoding="iso-8859-1" ?>
<newsitem itemid="134638" id="root" date="1996-10-22" xml:lang="en">
<title>UK: SmithKline Beecham profits surge, margins held.</title>
<headline>SmithKline Beecham profits surge, margins held.</headline>
<dateline>LONDON 1996-10-22</dateline>
<text>
<p>Anglo-American pharmaceuticals giant SmithKline Beecham Plc on Tuesday reported a 20 percent surge in third quarter pretax profits to 374 million stg, with sales rising 15 percent to two billion stg.</p>
<p>The third quarter dividend payout was 4.0 pence per share, payable on December 31. SmithKline said its operating margins in the three month period had been held despite a 25 percent hike in spending on research and development.</p>
<p>Jan Leschly, chief executive, said in a statement &quot;We are particularly pleased with our overall performance which is driven by volume increases.  </p>
<p>&quot;In particular, excellent new product sales growth of 44 percent was a major contributor to the pharmaceutical sales increase of 18 percent,&quot; he said. The division's profits rose 20 percent during the period.</p>
<p>SmithKline cited in particular North American pharmaceutical sales growth of 33 percent.</p>
<p>Looking at some of the products in pharmaceuticals, the Seroxat/Paxil antidepressant saw sales up 54 percent to 189 million. The Relafen/Relifex sales were up 33 percent to 85 million. Kytril was up 33 percent also to 46 million.</p>
<p>In the consumer healthcare unit, sales rose 11 percent, with trading profit up five percent. Promotional expenses were reported to have hit margins.</p>
<p>Over the counter product sales rose nine percent. Oral care products rose 23 percent and nutritional healthcare sales rose seven percent.</p>
<p>In the clinical laboratories unit sales edged one percent ahead, with trading profit up 16 percent assisted by &quot;vigorous implementation of cost management measures.&quot;</p>
<p>-- London Newsroom +44 171 5427717</p>
</text>
<copyright>(c) Reuters Limited 1996</copyright>
<metadata>
<codes class="bip:countries:1.0">
  <code code="UK">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1996-10-22"/>
  </code>
  <code code="USA">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1996-10-22"/>
  </code>
</codes>
<codes class="bip:industries:1.0">
  <code code="I25700">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1996-10-22"/>
  </code>
</codes>
<codes class="bip:topics:1.0">
  <code code="C15">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1996-10-22"/>
  </code>
  <code code="C151">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1996-10-22"/>
  </code>
  <code code="CCAT">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1996-10-22"/>
  </code>
</codes>
<dc element="dc.date.created" value="1996-10-22"/>
<dc element="dc.publisher" value="Reuters Holdings Plc"/>
<dc element="dc.date.published" value="1996-10-22"/>
<dc element="dc.source" value="Reuters"/>
<dc element="dc.creator.location" value="LONDON"/>
<dc element="dc.creator.location.country.name" value="UK"/>
<dc element="dc.source" value="Reuters"/>
</metadata>
</newsitem>
